|
Abstract:
The induction of tumor-specific T cells remains a primary obstacle to immunotherapeutic approaches for most cancers including prostate cancer. This difficulty has been largely ascribed to mechanisms for tumor evasion of the immune system and host-imposed restrictions (collectively referred to as tolerance) that prevent cross-reactive autoimmunity against the parent tissues from which tumors arise. Limitations in techniques to identify novel and truly immunogenic prostate-specific antigens and efficient methods to modify autologous tissues for vaccine preparation have further constrained approaches to develop immune-based therapies for prostate cancer. Hence, relatively straightforward manipulations that induce specific T cell responses against prostate tumors or epithelial tissues, especially in vivo, might ultimately prove valuable for prostate cancer immunotherapy. Our studies explore a new paradigm in which we will exploit blockade of T cell purigenic receptors A2a and A2b (using caffeine) to alleviate tumor-induced impairments in T cell function to potentiate T cellmediated immunotherapeutic responses to treat established prostate tumors in mice.
| Limitations: |
 APPROVED FOR PUBLIC RELEASE |
| Description: |
Annual rept. 1 Apr 2004-31 Mar 2005 |
| Pages: |
7 |
| Report Date: |
APR 2005 |
| Contract Number: |
DAMD170310108 |
| Report Number: |
A267064 |
|
|
|
|
|
Keywords relating to this report:
Email This Abstract
